Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
14.86 EUR | +0.81% | +4.94% | +51.32% |
Apr. 11 | Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating | MT |
Apr. 08 | Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+51.32% | 993M | |
+2.03% | 42.59B | |
+7.48% | 40.65B | |
+49.11% | 40.57B | |
-11.96% | 26.77B | |
+8.34% | 24.81B | |
-23.92% | 18.17B | |
+27.40% | 12.05B | |
-2.77% | 11.7B | |
+7.02% | 11.1B |
- Stock Market
- Equities
- ABVX Stock
- News Abivax
- Abivax : Surges 40% After Ulcerative Colitis Drug Demonstrates Efficacy In Mid-Stage Study